Literature DB >> 33597176

Monoclonal antibodies for treating COVID-19.

Andrea M Pallotta1, ChungYun Kim2, Steven M Gordon3, Alice Kim4.   

Abstract

Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Entities:  

Year:  2021        PMID： 33597176     DOI： 10.3949/ccjm.88a.ccc074

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  2 in total

1.  Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.

Authors:  Mark Jarrett; Warren Licht; Kevin Bock; Zenobia Brown; Jamie Hirsch; Kevin Coppa; Rajdeep Brar; Stephen Bello; Ira Nash
Journal:  JMIRx Med       Date:  2021-09-27

2.  Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.

Authors:  Bjoern Jensen; Nadine Luebke; Torsten Feldt; Verena Keitel; Timo Brandenburger; Detlef Kindgen-Milles; Matthias Lutterbeck; Noemi F Freise; David Schoeler; Rainer Haas; Alexander Dilthey; Ortwin Adams; Andreas Walker; Joerg Timm; Tom Luedde
Journal:  Lancet Reg Health Eur       Date:  2021-07-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.